274 related articles for article (PubMed ID: 3546139)
1. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
Dromer F; Salamero J; Contrepois A; Carbon C; Yeni P
Infect Immun; 1987 Mar; 55(3):742-8. PubMed ID: 3546139
[TBL] [Abstract][Full Text] [Related]
2. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
[TBL] [Abstract][Full Text] [Related]
3. An anti-Cryptococcus neoformans monoclonal antibody directed against galactoxylomannan.
van de Moer A; Salhi SL; Cherniak R; Pau B; Garrigues ML; Bastide JM
Res Immunol; 1990 Jan; 141(1):33-42. PubMed ID: 2189167
[TBL] [Abstract][Full Text] [Related]
4. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
Eckert TF; Kozel TR
Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
[TBL] [Abstract][Full Text] [Related]
5. Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.
Ikeda R; Nishimura S; Nishikawa A; Shinoda T
Clin Diagn Lab Immunol; 1996 Jan; 3(1):89-92. PubMed ID: 8770510
[TBL] [Abstract][Full Text] [Related]
6. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
Casadevall A; Scharff MD
J Exp Med; 1991 Jul; 174(1):151-60. PubMed ID: 1676047
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
8. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
10. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
11. Immunoelectronmicroscopic characterization of monoclonal antibodies (MAbs) against Cryptococcus neoformans.
Todaro-Luck F; White EH; Reiss E; Cherniak R
Mol Cell Probes; 1989 Dec; 3(4):345-61. PubMed ID: 2482437
[TBL] [Abstract][Full Text] [Related]
12. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
13. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
[TBL] [Abstract][Full Text] [Related]
14. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.
Spiropulu C; Eppard RA; Otteson E; Kozel TR
Infect Immun; 1989 Oct; 57(10):3240-2. PubMed ID: 2476401
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
16. [The isolation of monoclonal antibodies to Cryptococcus neoformans antigens].
Khrapova NP; Lesovoĭ VS; Prokhvatilova EV; Stupenko LN; Zharkova SF
Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):70-4. PubMed ID: 10876856
[TBL] [Abstract][Full Text] [Related]
17. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
18. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide.
Dromer F; Gueho E; Ronin O; Dupont B
J Clin Microbiol; 1993 Feb; 31(2):359-63. PubMed ID: 8432823
[TBL] [Abstract][Full Text] [Related]
19. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
Schlageter AM; Kozel TR
Infect Immun; 1990 Jun; 58(6):1914-8. PubMed ID: 2187813
[TBL] [Abstract][Full Text] [Related]
20. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]